Results 91 to 100 of about 1,093,493 (290)

Research progress on the role of inflammatory mediators in the pathogenesis of epilepsy

Ibrain, Volume 11, Issue 1, Page 44-58, Spring 2025.
In the central nervous system, activated immune cells lead to the overproduction of inflammatory mediators through the corresponding signal pathway. Under the stimulation of inflammatory factors, neuroinflammation ultimately occurs. Overexpression of inflammatory mediators and activated immunocytes plays an important role in the emergence and ...
Yue Yu, Fei‐Ji Sun
wiley   +1 more source

Kinase inhibitors: a new class of antirheumatic drugs [PDF]

, 2012
Vasileios C KyttarisDivision of Rheumatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USAAbstract: The outlook for patients with rheumatoid arthritis has improved significantly over the last three decades with the use
Kyttaris VC, Kyttaris, Vasileios
core   +1 more source

The Role of High Cxcl11 Expression in Ovarian Dysfunction Through NF‐κB and AKT Pathways in a Thin Endometrium Mouse Model

iNew Medicine, EarlyView.
Thin endometrium upregulates Cxcl11, which polarizes ovarian macrophages via NF‐κB/AKT, impairing ovarian function. A new uter‐ovarian signaling axis is identified. ABSTRACT Objective Thin endometrium (TE) is a recognized cause of female infertility, primarily associated with impaired uterine receptivity.
Yulu Yang, Fei Tang, Zihan Meng, Yunxi Bao, Jujun Han, Xiaohua Jiang, Jianye Wang, Ying Wang, Zhaolian Wei   +8 more
wiley   +1 more source

Successful treatment of the dupilumab-induced psoriatic dermatitis/arthritis and atopic dermatitis with a JAK inhibitor: A case report and literature review

Journal of Allergy and Clinical Immunology: Global
Dupilumab-induced psoriatic dermatitis and arthritis in a patient with atopic dermatitis were effectively managed with upadacitinib, highlighting the use of Janus kinase inhibitors as a possible treatment for biologic therapy side effects.
Misuzu Tsunoda, MD, Takeya Adachi, MD, PhD, Yuuri Nakajima, MD, Yoshihiro Yatomi, MD, Tomoko Shimizu, MD, PhD, Katsuki Nakasute, MD   +5 more
doaj   +1 more source

Tofacitinib Regulates β‐Catenin Nuclear Translocation to Inhibit FLS Migration and Alleviate Clinical Symptoms of RA

iNew Medicine, EarlyView.
ABSTRACT Objective Tofacitinib is a Janus kinase (JAK) inhibitor approved for the treatment of moderate‐to‐severe rheumatoid arthritis (RA). However, its synovium‐related molecular mechanisms, particularly its regulatory effect on fibroblast‐like synoviocyte (FLS) migration, remain incompletely understood.
Shuqi Fang, Tianjing Zhang, Ling Hu, Ruijin Liu, Leyi Jia, Menglin Bai, Jiale Dong, Yuchen Zhao, Han Wang, Lei Zhang, Tao Li, Youcai Deng, Xianzheng Zhang, Lingling Zhang   +13 more
wiley   +1 more source

Janus kinase inhibitors in dermatology: Part II. A comprehensive review

, 2021
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular signaling pathway is implicated in the pathogenesis of a number of inflammatory dermatoses. Clinical trials and other studies have demonstrated the efficacy of JAK
Chapman, Stephanie, Lim, Henry W, Stein Gold, Linda F   +2 more
core   +1 more source

Safety of Janus kinase inhibitors in rheumatology: current state of the issue

Современная ревматология
This review presents current data on the safety of Janus kinase inhibitors (JAKi) in patients with immune-mediated rheumatic diseases. Special attention is given to the risks of infections, cardiovascular complications, and malignancies.
B. S. Belov, N. V. Muravyeva, M. M. Baranova   +2 more
doaj   +1 more source

Therapeutic effects of janus kinase inhibitors

Janus kinase (JAK) inhibitors are small synthetic molecules which can easily enter the intracellular space and inhibit janus kinases, which renders the janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway to be nonfunctional.
Ntwali, Arnaud
core  

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source

Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report

Multiple Sclerosis Journal - Experimental, Translational and Clinical
Janus kinase inhibitors (JAKis), such as baricitinib, target the Janus kinase/signal transducers and activators of transcription pathway to regulate proinflammatory cytokines and T-helper cell activity, thereby reducing inflammation.
Rozita Khalili, Ahmad A. Toubasi, Meryim Poursheykhi, Francesca Bagnato   +3 more
doaj   +1 more source